These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

610 related items for PubMed ID: 16483179

  • 1. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
    Yilmaz M, Biri A, Karakoç A, Törüner F, Bingöl B, Cakir N, Tiras B, Ayvaz G, Arslan M.
    J Endocrinol Invest; 2005 Dec; 28(11):1003-8. PubMed ID: 16483179
    [Abstract] [Full Text] [Related]

  • 2. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
    Yilmaz M, Karakoç A, Törüner FB, Cakir N, Tiras B, Ayvaz G, Arslan M.
    Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907
    [Abstract] [Full Text] [Related]

  • 3. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
    Yilmaz M, Bukan N, Ayvaz G, Karakoç A, Törüner F, Cakir N, Arslan M.
    Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
    Ortega-González C, Cardoza L, Coutiño B, Hidalgo R, Arteaga-Troncoso G, Parra A.
    J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA, Shin SY, Yoon BK, Choi D.
    Gynecol Endocrinol; 2007 Jan; 23(8):461-7. PubMed ID: 17852414
    [Abstract] [Full Text] [Related]

  • 8. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance.
    Tan S, Hahn S, Benson S, Dietz T, Lahner H, Moeller LC, Schmidt M, Elsenbruch S, Kimmig R, Mann K, Janssen OE.
    Eur J Endocrinol; 2007 Nov; 157(5):669-76. PubMed ID: 17984248
    [Abstract] [Full Text] [Related]

  • 9. Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease.
    Dereli D, Dereli T, Bayraktar F, Ozgen AG, Yilmaz C.
    Endocr J; 2005 Jun; 52(3):299-308. PubMed ID: 16006724
    [Abstract] [Full Text] [Related]

  • 10. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
    Singh S, Akhtar N, Ahmad J.
    Diabetes Metab Syndr; 2012 Jun; 6(4):207-11. PubMed ID: 23199540
    [Abstract] [Full Text] [Related]

  • 11. Effects of Metformin Treatment on Soluble Leptin Receptor Levels in Women with Polycystic Ovary Syndrome.
    Liu RB, Liu Y, Lv LQ, Xiao W, Gong C, Yue JX.
    Curr Med Sci; 2019 Aug; 39(4):609-614. PubMed ID: 31346998
    [Abstract] [Full Text] [Related]

  • 12. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
    Ganie MA, Khurana ML, Nisar S, Shah PA, Shah ZA, Kulshrestha B, Gupta N, Zargar MA, Wani TA, Mudasir S, Mir FA, Taing S.
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
    [Abstract] [Full Text] [Related]

  • 13. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance.
    Sepilian V, Nagamani M.
    J Clin Endocrinol Metab; 2005 Jan; 90(1):60-5. PubMed ID: 15483106
    [Abstract] [Full Text] [Related]

  • 14. Exploring the significance of sex hormone-binding globulin examination in the treament of women with polycystic ovarian syndrome (PCOS).
    Lin XF, Wu RR, Du J, Liao YC, Du Y, Ye Y, Wang Y, Zhang XB, Wu C, Chen A.
    Clin Exp Obstet Gynecol; 2015 Jan; 42(3):315-20. PubMed ID: 26152001
    [Abstract] [Full Text] [Related]

  • 15. Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
    Diri H, Karaburgu S, Acmaz B, Unluhizarci K, Tanriverdi F, Karaca Z, Kelestimur F.
    Gynecol Endocrinol; 2016 Jan; 32(1):42-5. PubMed ID: 26370923
    [Abstract] [Full Text] [Related]

  • 16. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS.
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
    [Abstract] [Full Text] [Related]

  • 17. Metabolic and androgen profile in underweight women with polycystic ovary syndrome.
    Anastasiou OE, Canbay A, Fuhrer D, Reger-Tan S.
    Arch Gynecol Obstet; 2017 Aug; 296(2):363-371. PubMed ID: 28608050
    [Abstract] [Full Text] [Related]

  • 18. Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome.
    Liao L, Tian YJ, Zhao JJ, Xin Y, Xing HY, Dong JJ.
    Chin Med J (Engl); 2011 Mar; 124(5):714-8. PubMed ID: 21518564
    [Abstract] [Full Text] [Related]

  • 19. Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial.
    Li Y, Tan J, Wang Q, Duan C, Hu Y, Huang W.
    Fertil Steril; 2020 Jan; 113(1):197-204. PubMed ID: 31718828
    [Abstract] [Full Text] [Related]

  • 20. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome.
    Belli SH, Graffigna MN, Oneto A, Otero P, Schurman L, Levalle OA.
    Fertil Steril; 2004 Mar; 81(3):624-9. PubMed ID: 15037412
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.